Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

Celgene Corp. (CELG)

Index:

Nasdaq 100

Add To Portfolio

$ 0.00

Closing Price Chg:

$0.00
52 Week High: $0.00
52 Week Low: $0.00

Currency: US Dollars
Shares Issued: 702.45m
Volume: 0

Celgene Corp. Overview

Celgene engages in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases in the United States. It operates in two segments: Human Pharmaceuticals and Stem Cell Therapies.

1 Day Chart (21-11-2024)

6 Month Chart

More Celgene Corp. charts

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

	Latest	F'cast
Div Yield	0.0%
Div Cover	n/a
Op Mrgn	34.0%
ROCE	218.1%

	Latest	F'cast
P/E	n/a
PEG	n/a
Pr/Revenue	n/a
Pr/Book	n/a

	Latest	F'cast
Revenue	17.7%
PBT	12.0%
EPS	49.9%
DPS	n/a

Celgene Corp. Fundamentals

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-14	7,563.80	2,327.40	249.00¢	n/a	n/a	+42%	n/a	0.0%
31-Dec-15	9,161.10	2,023.50	202.00¢	n/a	n/a	-19%	n/a	0.0%
31-Dec-16	11,185.00	2,372.00	257.00¢	45.0	1.7	+27%	n/a	0.0%
31-Dec-17	12,973.00	4,314.00	377.00¢	27.7	0.6	+47%	n/a	0.0%
31-Dec-18	15,265.00	4,832.00	565.00¢	11.3	0.2	+50%	n/a	0.0%

Celgene Corp. ShareCast News

Bristol Myers acquires Celgene in $74bn pharma d...	03-Jan-2019	ShareCast
Juno Therapeutics surges on Celgene deal	22-Jan-2018	ShareCast
Trump calls on drug giants to boost US productio...	31-Jan-2017	ShareCast

More Celgene Corp. ShareCast news

Celgene Corp. Top Newspaper Links

For Biotech, a Tax Break Spells Hope	10-Dec-2008	New York Times
Celgene to buy Pharmion	19-Nov-2007	LA Times
Celgene to Acquire Pharmion	19-Nov-2007	New York Times